Technical Analysis for PLRX - Pliant Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Lower Bollinger Band Walk | Weakness | -0.47% | |
| Outside Day | Range Expansion | -0.47% | |
| Lower Bollinger Band Touch | Weakness | -0.47% | |
| Oversold Stochastic | Weakness | -0.47% | |
| MACD Bearish Centerline Cross | Bearish | 3.33% | |
| Volume Surge | Other | 3.33% | |
| NR7 | Range Contraction | 3.33% |
| Alert | Time |
|---|---|
| Lower Bollinger Band Support | about 18 hours ago |
| Possible NR7 | about 18 hours ago |
| Possible Inside Day | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 20 hours ago |
| Down 3% | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
Pliant Therapeutics, Inc. Description
Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Alcohol Orphan Drug Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Hepatology Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Drug Design Liver Fibrosis Primary Sclerosing Cholangitis Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Muscular Dystrophies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.62 |
| 52 Week Low | 10.22 |
| Average Volume | 454,682 |
| 200-Day Moving Average | 13.39 |
| 50-Day Moving Average | 13.07 |
| 20-Day Moving Average | 14.05 |
| 10-Day Moving Average | 13.54 |
| Average True Range | 0.88 |
| RSI (14) | 41.52 |
| ADX | 27.22 |
| +DI | 17.82 |
| -DI | 28.53 |
| Chandelier Exit (Long, 3 ATRs) | 13.46 |
| Chandelier Exit (Short, 3 ATRs) | 14.40 |
| Upper Bollinger Bands | 15.95 |
| Lower Bollinger Band | 12.14 |
| Percent B (%b) | 0.15 |
| BandWidth | 27.15 |
| MACD Line | -0.20 |
| MACD Signal Line | 0.12 |
| MACD Histogram | -0.3192 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.51 | ||||
| Resistance 3 (R3) | 13.43 | 13.08 | 13.38 | ||
| Resistance 2 (R2) | 13.08 | 12.88 | 13.13 | 13.34 | |
| Resistance 1 (R1) | 12.91 | 12.76 | 13.00 | 12.99 | 13.29 |
| Pivot Point | 12.56 | 12.56 | 12.61 | 12.61 | 12.56 |
| Support 1 (S1) | 12.39 | 12.36 | 12.48 | 12.47 | 12.17 |
| Support 2 (S2) | 12.04 | 12.24 | 12.09 | 12.12 | |
| Support 3 (S3) | 11.87 | 12.04 | 12.08 | ||
| Support 4 (S4) | 11.95 |
